Search results for “Mofetil mycophenolate” companies
Free sign up to view the full data
Key Players
Order by:
Innovation Intensity
With the analysis among 71 patents, we discovered top 17 key players by total patent application. SyntheX, Inc., Ares Trading SA, Novartis AG are dominant in this area. They take 53.52% of the total patent filing.
STARTUP
SyntheX, Inc.
California, United States
Patent: 26
Ares Trading SA
Switzerland
Patent: 7
Novartis AG
Basel-Stadt, Switzerland
Patent: 5
ZymoGenetics, Inc.
Washington, United States
Patent: 4
Roche Palo Alto LLC
California, United States
Patent: 4
F. Hoffmann-La Roche Ltd.
Switzerland
Patent: 3
TEVA PHARMS USA
New Jersey, United States
Patent: 2
Korea Disease Control & Prevention Agency
South Korea
Patent: 2
DSM IP Assets BV
Netherlands
Patent: 2
Gilead Sciences, Inc.
California, United States
Patent: 1
Startups & Unicorns
Order by:
Innovation Intensity
With the analysis among 26 patents, we discovered top 1 start-ups by total patent application.
STARTUP
SyntheX, Inc.
California, United States
Patent: 26
Fast-Growing
Order by:
Innovation in recent 5 years
With the analysis among related 1 patents applied in the last 5 years. We discover 1 most active companies in this area.
Affiliated Hospital of Jiangsu University
undefined undefined
Patent: 1
New Entrants
Order by:
Innovation in recent 5 years
With the analysis among related 1 patents in last 5 years, we discover 1 new entrants.
Affiliated Hospital of Jiangsu University
undefined undefined
Patent: 1
Research Institutions
Order by:
Innovation Intensity
No data, please try another search term
Keywords Quick Entry
Popular
Physics
Chemistry
Engineering
Materials science
Computer science
Biology
Medicine
MetalElectrodeVoltageSemiconductorPolymerElectricityCoatingFiberDisplay deviceRaw materialElectric motorUltimate tensile strengthNozzleCarbonBuilding constructionAlkylService lifeElectronOxideOxygenSolventControl unitFlangeControl systemDrugLight sourcePistonDiseaseElectric powerHigh pressure
View more
Page generation time: